Martine Zimmermann
Director/Board Member en INVENTIVA .
Fortuna: 181 315 $ al 29/02/2024
Perfil
Presently, Martine Zimmermann holds the position of SVP, Head-Regulatory Affairs, R&D Quality at Ipsen Biopharmaceuticals, Inc. She is also on the board of Ligand Pharmaceuticals, Inc. and Inventiva SA.
Dr. Zimmermann previously held the position of Senior VP & Head-Global Regulatory Affairs at Alexion Pharmaceuticals, Inc.
She received a doctorate from Louis Pasteur University and a doctorate from the University of Strasbourg.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
22/09/2023 | 2 285 ( 0.01% ) | 181 315 $ | 29/02/2024 |
Cargos activos de Martine Zimmermann
Empresas | Cargo | Inicio |
---|---|---|
INVENTIVA | Director/Board Member | 16/04/2021 |
LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 |
Ipsen Biopharmaceuticals, Inc. | General Counsel | - |
Antiguos cargos conocidos de Martine Zimmermann.
Empresas | Cargo | Fin |
---|---|---|
ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/02/2023 |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/01/2021 |
Formación de Martine Zimmermann.
University of Strasbourg | Doctorate Degree |
Louis Pasteur University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
INVENTIVA | Health Technology |
Empresas privadas | 3 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |